Shilpa Medicare launches dedicated Shilpa CDMO for complex small molecules ahead of CPHI Milan
The standalone entity brings 230 kL reactor capacity, 400+ scientists and specialist teams for HPAPIs, PROTACs, oligonucleotides and ADC payloads — with proximity to Shilpa Biologicals enabling integrated ADC development within a 200-mile supply chain